Search News Archives
Social Media
Will BRIC be the Savior for the Life Sciences and Medical Devices Sector? Seal of Approval for Pepceuticals ZEISS Lightsheet Z.1 awarded with Best New Life Science Product of 2012 IDT and SGI-DNA Broaden Their Collaboration to Provide Synthetic DNA Products up to 2 Mbp Watson-Marlow OEM pumps help push the boundaries of automated cell culture Breakthrough in non-invasive gut health testing New Portable SPECTROSCOUT XRF Analyzer - the Lab that Goes Anywhere ZEISS SIGMA used to analyze Russian meteorite that fell in Chelyabinsk region
Waters Updates Alliance HPLC Designs Without Impacting Established Validated Methods Porvair Sciences Expands Product Range for Epigenetics Thermo Fisher Scientific Introduces Gas Chromatography Headspace Autosampler for Organic Volatiles New Amicon® Pro Purification System for Protein Purification from Merck Millipore Wyatt Calypso Succeeds in ABRF-MIRG Study Revolutionize your pipetting with the new Biohit Picus electronic pipette Easy, Reliable Weighing in Regulated Areas Phenom proX all-in-one desktop SEM Flash of inspiration in the shaft tunnel - IKA launches the new video for UTTD control The only Chromatography Autosampler you will ever need! JG Finneran Associates introduces the 96-Well Multi-Tier Microtiter Plate System (Patented) IC for the people – Metrohm celebrates 25 years of ion chromatography
For further information or to sign up to receive any of our E-Newsletters click here Reading and Imaging are Combined in BioTek's Revolutionary, New Cytation™3 ZEISS SIGMA used to analyze Russian meteorite that fell in Chelyabinsk region New SPOT Insight™ Gigabit Camera Brings Microscopy Presentations to Life ZEISS Lightsheet Z.1 awarded with Best New Life Science Product of 2012 Malvern’s Dr E Neil Lewis takes his place among chemical imaging pioneers Waters Biopharmaceutical, Bioanalysis and Screening Solutions Now Shipping with UNIFI 1.6 New Software for Research & Scientific Thermal Imagers Thermo Fisher Scientific Introduces Data System to Unite Chromatography and Mass Spectrometry Molecular Devices Introduces SoftMax Pro 6 GxP Microplate Data Acquisition and Analysis Software Short Guide to 3D Cell Culture New EFS Handbook Published by Lee Products The Perfect Ultrafiltration Device for Your Specific Need Electron Magnetic Resonance shrinks to fit the undergraduate curriculum Biotage Releases New Catalog and Technical Guide for Sample Preparation and Evaporation New Waters Quality Parts, Chromatography Columns and Supplies Catalog
|
BioGenes to Develop Specific HCP Assay for Boehringer Ingelheim
publication date: Jul 5, 2012
|
author/source: BioGenes
BioGenes GmbH, a specialist in immunoassay and
sophisticated antibody development, today announced that it has signed a
collaboration agreement with Boehringer Ingelheim to develop several
product-specific host cell protein (HCP) assays for late stage drug substances.
 Proof of HCP depletion during the
purification process is an essential part of release testing and the regulatory
compliance documentation. HCPs can still be present at significant
concentrations even after the last purification step of the drug substance.
BioGenes develops highly sensitive HCP assays that can detect HCPs at very low
levels."BioGenes will provide on-call assay development capacities to both speed up the development and disburden Boehringer Ingelheim's inhouse capabilities," said Dr. Alexander Knoll, Managing Director of BioGenes. Product-specific HCP assays are usually required in clinical phase III studies to demonstrate consistency of manufacturing. In the early process development phase as well as in early clinical phases, generic assays available as off-the shelf kits are usually acceptable. About BioGenes BioGenes GmbH specializes in highly sophisticated and customized antibody and immunoassay development and is an experienced and reliable partner for process development improvements in all areas of quality control, diagnostics and drug discovery. BioGenes is certified to meet the international requirements and regularities of quality assurance and animal welfare. The Company maintains long-term relationships with research institutes, universities and biotech and pharmaceutical companies, which include eight of the ten largest pharmaceutical companies in the world. About Boehringer Ingelheim The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine. Today, Boehringer Ingelheim is one of the world's leading companies for contract development and manufacture of biopharmaceuticals. All types of services from mammalian cell line or microbial strain development to final drug production can be delivered within a one-stop-shop concept. Boehringer Ingelheim delivers services for pre-clinical development up to global market supply with a strong commitment to its customers at its global manufacturing facilities for mammalian cell culture and microbial fermentation. Boehringer Ingelheim has brought 19 molecules to market and has many years of experience in multiple molecule classes such as monoclonal antibodies, recombinant proteins, interferons, enzymes, fusion molecules and plasmid DNA. Furthermore, high-titer platform technologies for new antibody mimetic formats such as scaffold proteins and antibody fragments are available for the manufacture of customer products. |
|
